(Celecoxib + famciclovir) is under clinical development by Virios Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect (Celecoxib + famciclovir)’s likelihood of approval (LoA) and phase transition for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) took place on 27 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Celecoxib + famciclovir) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

(Celecoxib + famciclovir) overview

IMC-1 a fixed dose combination of celecoxib and famciclovir is under development for the treatment of irritable bowel disease and chronic fatigue syndrome. The drug candidate is an oral medication that is designed to suppress the suspected tissue-resident herpes virus and to alleviate fibromyalgia symptoms. It acts by targeting DNA polymerase and Prostaglandin G/H Synthase 2. 

The drug candidate was under development for the treatment of fibromyalgia.

Virios Therapeutics overview

Virios Therapeutics, formerly Innovative Med Concepts LLC is a biotech company that develops novel treatments for the treatment of fibromyalgia and other related syndromes. The company’s pipeline products include NRP-1, a throat spray that is used to treat viral pharyngitis that provides relief to cancer patients undergoing head and neck radiation; and IMC-1, a novel proprietary fixed dose combination medication that is designed to treat chronic tissue-resident herpes simplex virus type 1. It also conducts research on various chronic ailments. The company collaborates with other organizations for their pipeline development, licensing, and commercialization. Virios Therapeutics is headquartered in Tuscaloosa, Alabama, the US.

Quick View (Celecoxib + famciclovir) LOA Data

Report Segments
  • Innovator
Drug Name
  • (Celecoxib + famciclovir)
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
Key Developers
  • Sponsor Company: Virios Therapeutics
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.